ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Final Regulations For Clinical Cancer Education Program Adopted

October 3, 1975

In Brief: Georgetown Professor Heads Cancer Therapy Evaluation Program; NCI-VA Branch Abolished

September 7, 1979

In The Courts: Lilly’s Claims Figured In Scripts Written To Coach Sales res, Court Documents Show

July 30, 1999

Cancer Clinical Trials System Needs Comprehensive Review, NCI Director Says

July 11, 2003

Clinical Trials Working Group Offers 21 Recommendations to improve efficiency of trials.

February 25, 2005

IOM Report: Seek More Comment From Public On Priorities, NIH Told

July 17, 1998